NL300013I2 - Nieuwe proteinen me TNF-remmende werking en hun bereiding. - Google Patents

Nieuwe proteinen me TNF-remmende werking en hun bereiding.

Info

Publication number
NL300013I2
NL300013I2 NL300013C NL300013C NL300013I2 NL 300013 I2 NL300013 I2 NL 300013I2 NL 300013 C NL300013 C NL 300013C NL 300013 C NL300013 C NL 300013C NL 300013 I2 NL300013 I2 NL 300013I2
Authority
NL
Netherlands
Prior art keywords
ala phe
pct
val ala
gln val
pro
Prior art date
Application number
NL300013C
Other languages
English (en)
Other versions
NL300013I1 (nl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25880678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300013(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DE1990/000719 external-priority patent/WO1991004176A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of NL300013I1 publication Critical patent/NL300013I1/nl
Publication of NL300013I2 publication Critical patent/NL300013I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NL300013C 1989-05-09 2000-07-24 Nieuwe proteinen me TNF-remmende werking en hun bereiding. NL300013I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3915072 1989-05-09
DE3922089A DE3922089A1 (de) 1989-05-09 1989-07-05 Neue proteine und ihre herstellung
PCT/DE1990/000719 WO1991004176A1 (de) 1989-09-20 1990-09-20 Plane insbesondere zum abdecken des lade- oder personenraumes von kraftfahrzeugen

Publications (2)

Publication Number Publication Date
NL300013I1 NL300013I1 (nl) 2000-10-02
NL300013I2 true NL300013I2 (nl) 2001-04-02

Family

ID=25880678

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300013C NL300013I2 (nl) 1989-05-09 2000-07-24 Nieuwe proteinen me TNF-remmende werking en hun bereiding.

Country Status (11)

Country Link
US (1) US5344915A (nl)
EP (1) EP0471701B2 (nl)
JP (6) JP3290651B2 (nl)
AT (1) ATE113063T1 (nl)
AU (1) AU633913B2 (nl)
CA (2) CA2050300C (nl)
DE (3) DE3922089A1 (nl)
ES (1) ES2063350T5 (nl)
HU (1) HU208162B (nl)
NL (1) NL300013I2 (nl)
WO (1) WO1990013575A1 (nl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479632B1 (en) * 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
ES2238070T3 (es) 1989-04-21 2005-08-16 Amgen Inc. Receptor del tnf, proteina ligante del tnf y adn codante para estos.
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0398327B2 (en) † 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
US6262239B1 (en) * 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992001002A1 (fr) * 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
WO1993004375A1 (en) * 1991-08-23 1993-03-04 Nchip, Inc. Burn-in technologies for unpackaged integrated circuits
EP0611302B1 (en) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
ATE242322T1 (de) * 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
AU5696198A (en) 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP1019508A1 (en) 1997-09-30 2000-07-19 PHARMACIA & UPJOHN COMPANY Tnf-related death ligand
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1259616A2 (en) 2000-03-02 2002-11-27 Xencor Tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
JP2006517191A (ja) * 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP3295957B1 (en) 2010-01-15 2019-08-07 Kirin-Amgen, Inc. Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR20160130248A (ko) 2014-03-31 2016-11-10 키린-암젠, 인코포레이티드 손발톱 및 두피 건선의 치료 방법
CN108727474B (zh) * 2018-06-11 2020-07-28 北京市农林科学院 具有消脂护肝功能的毛木耳提取物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
ATE107362T1 (de) * 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
US5344915A (en) 1994-09-06
DE10075019I1 (de) 2000-09-21
DE3922089A1 (de) 1990-12-13
ATE113063T1 (de) 1994-11-15
AU5532490A (en) 1990-11-29
JP4001604B2 (ja) 2007-10-31
JP3290651B2 (ja) 2002-06-10
ES2063350T5 (es) 2007-09-16
NL300013I1 (nl) 2000-10-02
WO1990013575A1 (de) 1990-11-15
HU208162B (en) 1993-08-30
JP2004043502A (ja) 2004-02-12
EP0471701B2 (de) 2007-03-07
DE59007517D1 (de) 1994-11-24
CA2425101A1 (en) 1990-11-15
JPH04505014A (ja) 1992-09-03
AU633913B2 (en) 1993-02-11
JP2002302500A (ja) 2002-10-18
HUT58352A (en) 1992-02-28
JP2007084554A (ja) 2007-04-05
CA2050300A1 (en) 1990-11-10
EP0471701A1 (de) 1992-02-26
HU903740D0 (en) 1992-01-28
CA2050300C (en) 2003-04-08
JP2005272473A (ja) 2005-10-06
EP0471701B1 (de) 1994-10-19
DE10075019I2 (de) 2005-06-23
JP2009167220A (ja) 2009-07-30
ES2063350T3 (es) 1995-01-01

Similar Documents

Publication Publication Date Title
NL300013I2 (nl) Nieuwe proteinen me TNF-remmende werking en hun bereiding.
NO965411L (no) N-terminalt forlengede proteiner uttrykt i gjær
NO942553D0 (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
ATE162201T1 (de) Cnp-gen und vorläuferprotein aus schwein
NO975565L (no) Benstimulerende faktor
ATE124955T1 (de) Substrat-peptide.
ATE140234T1 (de) Neue inhibitorische peptide
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
Tonoike et al. Amino acid sequence of an amyloidogenic Bence Jones protein in myeloma‐associated systemic amyloidosis
IL115825A0 (en) Therapeutic protein
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция
GEP19981435B (en) Peptides with Organo-Protective Activity, Pharmaceutical Composition and the Use Thereof